Toronto Stock Exchange · Healthcare
Invest in Helix BioPharma stock from India
Indian and foreign residents can buy Helix BioPharma (HBP) shares directly through Paasa.
By Paasa · Updated
Helix BioPharma at a glance
- Price
- CA$1.14+CA$0.11 (10.68%)
- Market cap
- CA$87.07M
- Day range
- CA$0.96 – CA$1.14
- P/E
- -25.91
- Dividend yield
- None
- Volume
- 14.76K
- 1 month
- -40.00%
- 6 months
- -38.04%
- YTD
- -51.90%
- 1 year
- -28.30%
- 5 years
- -60.69%
Helix BioPharma statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CA$0.0 | CA$0.0 | CA$0.0 | CA$0.0 | CA$0.0 |
| Gross profit | −CA$10.0K | −CA$14.0K | −CA$13.0K | −CA$12.0K | −CA$173.0K |
| Operating income | −CA$5.4M | −CA$9.4M | −CA$6.3M | −CA$6.5M | −CA$9.6M |
| Net income | −CA$5.2M | −CA$9.3M | −CA$6.3M | −CA$6.1M | −CA$7.9M |
| Earnings per share | −CA$0.09 | −CA$0.21 | −CA$0.16 | −CA$0.20 | −CA$0.29 |
| EBITDA | −CA$5.2M | −CA$9.4M | −CA$6.3M | −CA$6.0M | −CA$9.5M |
| Total assets | CA$18.8M | CA$1.5M | CA$1.0M | CA$3.7M | CA$4.1M |
| Total debt | CA$336.0K | CA$0.0 | CA$0.0 | CA$2.5M | CA$3.6M |
| Cash and short-term investments | CA$65.0K | CA$1.1M | CA$808.0K | CA$3.3M | CA$3.6M |
| Shareholders' equity | CA$15.6M | −CA$90.0K | −CA$844.0K | CA$319.0K | −CA$1.4M |
| Operating cash flow | −CA$3.8M | −CA$5.2M | −CA$5.5M | −CA$6.5M | −CA$9.3M |
| Free cash flow | −CA$3.8M | −CA$5.2M | −CA$5.5M | −CA$6.5M | −CA$9.3M |
| Capital expenditure | −CA$2.0K | −CA$14.0K | −CA$10.0K | CA$0.0 | CA$0.0 |
Fiscal years as reported, the latest ending 31 Jul 2025. Figures in CAD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Cybin | CYBN.NE | CA$17.80 | CA$430.86M |
| Cardiol Therapeutics | CRDL.TO | CA$2.39 | CA$275.50M |
| Satellos Bioscience | MSCL.TO | CA$12.62 | CA$262.89M |
| Quipt Home Medical | QIPT.TO | CA$4.98 | CA$221.44M |
| Jushi | JUSH.CN | $0.93 | $185.72M |
| Cannara Biotech | LOVE.V | CA$1.89 | CA$181.03M |
| HLS Therapeutics | HLS.TO | CA$4.00 | CA$125.10M |
| Resverlogix | RVX.TO | CA$0.10 | CA$34.39M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Helix BioPharma from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to CAD when you buy.
Step 3
Search HBP and buy
Find Helix BioPharma by name or by its ticker, HBP, and place your order.
Why invest in Helix BioPharma from India
What Helix BioPharma does
Based in Richmond Hill, Canada, Helix BioPharma Corp. is a Canadian immune-oncology company focused on therapeutic development. The firm is progressing L-DOS47 for treating non-small cell lung cancer and is also working on V-DOS47, which targets the vascular epithelial growth factor receptor 2. Helix BioPharma operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Helix BioPharma stock from India?
Yes. Indian residents and NRIs can buy Helix BioPharma (HBP) shares directly through Paasa. Helix BioPharma is listed on the Toronto Stock Exchange, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell Helix BioPharma shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the CAD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.